
Cell and Gene Therapy Sector Enters ‘Critical’ Period After Marks’ FDA Exit
As head of the FDA’s Center for Biologics Evaluation and Research, Peter Marks was a staunch advocate for cell and gene therapies, particularly their use for rare diseases. Despite Marks’ controversial departure last month, it appears his agenda may at …